AIM ImmunoTech Aktie - HXB2

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Current Price

0,114

Gebot

0,111

Fragen

0,117

Volumen

0,00

0,00 Tagesbereich 0,00

0,113 52-Wochen-Bereich 0,60

Handelsende

0,113

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

8.218

Finanzvolumen

VWAP

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian...

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition...

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic...

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast OCALA, Fla., May 09...

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen® OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech...

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for...

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the...

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Year marked by growing body of...

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast OCALA...

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.01	-8.06451612903	0.124	0.124	0.116	5793	0.11664469	DE
4	-0.032	-21.9178082192	0.146	0.146	0.113	9279	0.12740571	DE
12	-0.067	-37.0165745856	0.181	0.246	0.113	8218	0.15474221	DE
26	-0.162	-58.6956521739	0.276	0.31	0.113	7595	0.18461164	DE
52	-0.21	-64.8148148148	0.324	0.6	0.113	5672	0.23329114	DE
156	-0.4509999	-79.8230052784	0.5649999	0.61	0.113	4759	0.27488016	DE
260	-0.4509999	-79.8230052784	0.5649999	0.61	0.113	4759	0.27488016	DE

HXB2 - Frequently Asked Questions (FAQ)

What is the current AIM ImmunoTech share price?

The current share price of AIM ImmunoTech is 0,114 €

What is the 1 year trading range for AIM ImmunoTech share price?

AIM ImmunoTech has traded in the range of 0,113 € to 0,60 € during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
E3O1Nexoptic Technology Corp	0,013 € (52,94%)	7,63k
VOPInvestigator Resources Ltd	0,0175 € (40,00%)	4,89k
IAHInternational Lithium Corp	0,0145 € (38,10%)	20,1k
K6SMira Pharmaceuticals Inc	1,20 € (37,93%)	3,67k
B5S0NU E Power Corp	0,283 € (36,06%)	76,19k
9COCorus Entertainment	0,0335 € (-43,70%)	460
C0MCCS Abwicklungs AG	0,08 € (-42,45%)	196,61k
47GAGo Metals Corp	0,0142 € (-36,61%)	4,13k
M0YNMynaric AG	0,866 € (-35,85%)	429,67k
WIG1Wige Media AG	0,017 € (-35,85%)	1,44M
D7GNel ASA	0,28 € (-11,81%)	36,74M
RQ0DWave Quantum Inc	6,384 € (19,95%)	3,19M
DRHDroneShield Limited	0,575 € (7,68%)	2,21M
DMLSayona Mining Limited	0,0115 € (-4,96%)	1,88M
WIG1Wige Media AG	0,017 € (-35,85%)	1,44M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

AIM ImmunoTech Inc (HXB2)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

HXB2 Neueste Nachrichten

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

HXB2 - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

AIM ImmunoTech Inc (HXB2) Börsenkurse

AIM ImmunoTech Inc (HXB2)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

HXB2 Neueste Nachrichten

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

HXB2 - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen